BRIEF-Vanda receives negative opinion for marketing authorization from the European Medicines Agency
November 10, 2017 at 16:10 PM EST
* Vanda receives negative opinion for marketing authorization from the European Medicines Agency on fanaptum™ for the treatment of schizophrenia